Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity awards granted on April 1, 2026 to a new non-executive employee hired in March 2026. The company granted 80,000 non-qualified stock options and 15,000 restricted stock units under its 2022 Inducement Equity Incentive Plan, subject to vesting and continued employment.
Options use the closing price on the grant date; options vest 25% after one year then monthly over three years, and RSUs vest one-third annually over three years. Grants were approved by the Compensation Committee as required by Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) selected rinzimetostat 400 mg once daily as the RP3D in combination with darolutamide for the Himalayas-1 global Phase 3 registrational trial, expected to initiate in 1H 2026. Early Phase 1b data (median follow-up ~5 months) show landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, a 47% PSA50 rate (7/15), and 71% achieving >50% ctDNA reduction (10/14). Safety at 400 mg was favorable: mostly Grade 1–2 TRAEs, one Grade 3 TRAE, rare dose modifications. Company plans a ~600-patient, 1:1 randomized Phase 3 with rPFS primary endpoint.
ORIC Pharmaceuticals (Nasdaq: ORIC) will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC).
The company will present results on a conference call and webcast on March 31, 2026 at 4:30pm ET; a replay will be available for 90 days.
ORIC (Nasdaq: ORIC) announced acceptance of multiple preclinical poster presentations on rinzimetostat (ORIC-944) at the AACR Annual Meeting, April 17-22, 2026 in San Diego. Posters (Abstracts 7120, 7132) report preclinical activity of rinzimetostat in PRC2 resistance contexts and combination activity with AR inhibitors in prostate cancer models.
Presentations are scheduled for April 22, 2026, 9:00 a.m.–12:00 p.m. PT in Poster Section 14, Session: Experimental and Molecular Therapeutics.
ORIC Pharmaceuticals (Nasdaq:ORIC) granted inducement equity awards to a new non-executive employee on March 2, 2026. The company awarded 14,800 non-qualified stock options and 2,400 restricted stock units under its 2022 Inducement Equity Incentive Plan.
The stock options carry an exercise price equal to ORIC's closing common stock price on the grant date. Vesting: 25% of options vest after one year, then monthly 1/36th thereafter; RSUs vest one-third on each of the first three anniversaries. Awards were approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) reported Phase 1b data for rinzimetostat in mCRPC and enozertinib in NSCLC, selected provisional RP2Ds, and initiated dose optimization with AR inhibitors. The company raised net proceeds totaling $264 million, reported $392.3M cash and investments (proforma $412.3M) and expects runway into 2H 2028.
ORIC plans multiple 2026 readouts and anticipates a Phase 3 registrational start for rinzimetostat in 1H 2026.
ORIC Pharmaceuticals (Nasdaq:ORIC) announced inducement equity grants made on February 2, 2026 to three new non-executive employees who joined in January 2026. ORIC granted 173,800 non-qualified stock options and 28,700 restricted stock units under its 2022 Inducement Equity Incentive Plan.
Options use the closing price on the grant date; options vest 25% after one year then monthly over 36 months, RSUs vest one-third each year for three years. Grants were approved by the Compensation Committee per Nasdaq Rule 5635(c)(4).
ORIC (Nasdaq: ORIC) announced management will participate in three investor conferences in February 2026 with fireside chats and one-on-one meetings.
Schedule: Guggenheim Emerging Outlook: Biotech Summit on Feb 12 at 10:30 a.m. ET; Citi Virtual Oncology Leadership Summit on Feb 18 at 2:30 p.m. ET; Oppenheimer Healthcare Life Sciences on Feb 25 at 12:00 p.m. ET. Webcasts and 90-day replays will be available via the company's investor website.
ORIC (NASDAQ: ORIC) reported 2025 operational highlights and 2026 milestones, emphasizing clinical progress for rinzimetostat (ORIC-944) in mCRPC and enozertinib in NSCLC. Key clinical metrics: rinzimetostat showed PSA50 in 55% (confirmed 40%), PSA90 in 20%, and ctDNA >50% reduction in 76% with 59% clearance. Enozertinib showed strong systemic activity (1L ORR 67% in EGFR exon 20; 80% in EGFR PACC) and 100% intracranial ORR in measurable CNS disease. Company selected provisional RP2Ds, plans a Phase 3 start for rinzimetostat in 1H 2026, and expects multiple 2026 readouts. Financials: raised $244M in 2025; cash and investments of $413M expected to fund operations into 2H 2028.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.
A live webcast will be available via the company’s investor website at www.oricpharma.com, and a replay will be accessible for 90 days after the event.